Hemophilia Treatment Company Catalyst Biosciences’ Antibody Update May Catalyze Shares
Catalyst Biosciences, Inc. (NASDAQ:CBIO) , a company that is developing improved treatments for hemophilia, expects to update investors on December 18, 2018 regarding its review of the neutralizing antibodies (nAB) observed in Cohort 6 of a phase I/II study earlier this year. The update by Catalyst should shed more light on the disappointment